RNS Number : 3782D
Aptamer Group PLC
17 November 2026

17 November 2026

**Aptamer Group plc**

("Aptamer", the "Company" or the "Group")

**Posting of Annual Report and Accounts and Notice of Annual General Meeting**

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic Optimer® binders, announces that the Annual Report and Accounts for the year ended 30 June 2026 and Notice of its 2026 Annual General Meeting (AGM) are being posted to shareholders today. These documents are available on the Company's website at https://aptamergroup.com/investors/reports-and-presentations/

Aptamer will host its AGM at 11.00 am GMT on Wednesday, 16 December 2026 at Windmill House, Innovation Way, York, YO10 5BR. The AGM will be held in person only, and no new information will be presented at the meeting.

The results of voting on all resolutions at the AGM will be announced to the London Stock Exchange and the full results of the voting published on the Company's website, as soon as practicable after the conclusion of the AGM.

**- Ends -**

**For further information, please contact:**

| | |
|---|---|
| **Aptamer Group plc** | +44 (0) 1904 217 404 |
| Dr Arron Tolley, Chief Executive Officer | |
| **SPARK Advisory Partners Limited - Nominated Adviser** | +44 (0) 20 3368 3550 |
| Andrew Emmott / Dillon Wall | |
| **Cavendish Capital Markets Limited – Joint Broker** | +44 (0) 20 7220 0500 |
| Geoff Nash / Seamus Fricker / Joe Smith | |
| **Turner Pope Investments (TPI) Limited – Joint Broker** | +44 (0) 20 3657 0050 |
| Andrew Thacker / Guy McDougall | |
| **Northstar Communications Limited - Investor Relations** | +44 (0) 113 730 3896 |
| Sarah Hollins | |

**About Aptamer Group**

Aptamer Group plc (AIM: APTA) develops Optimer® binders, next-generation synthetic alternatives to antibodies that offer high specificity, improved stability, lower cost and access to targets beyond the reach of conventional modalities.

The Group operates a dual-revenue model, generating near-term revenues through fee-for-service discovery programmes while building a portfolio of proprietary therapeutic assets designed to create long-term value through licensing, royalties and supply agreements.

Aptamer is strategically focused on two of the most significant challenges in modern drug development: targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its proprietary Optimer® platform, supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine, is designed to accelerate the identification of high-quality binders against challenging biological targets.

The Group's internal pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes, with upcoming in vivo studies expected to support future partnering and licensing opportunities.

Founded in 2008 and headquartered in York, UK, Aptamer works with many of the world's leading pharmaceutical companies, combining platform expertise, proprietary data and therapeutic innovation to create shareholder value.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAKZMMMKVDGVZM